The Management of Hypertension With Angiotensin Receptor Blockers in Special Populations

Clinical Cornerstone

Volumn 9, Issue SUPPL. 3, 2009, Pages

  Ferdinand, Keith C ^a   Taylor, Cheryl ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; NEBIVOLOL; NITRENDIPINE; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

AFRICAN AMERICAN; ALBUMINURIA; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASIAN; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; ENZYME INHIBITION; ETHNICITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MANAGED CARE; MICROALBUMINURIA; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; POPULATION RESEARCH; PREVALENCE; RACE DIFFERENCE; SYSTOLIC DYSFUNCTION;

EID: 65349125285     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1098-3597(09)60014-4     Document Type: Article

References (35)

1. Rosamond W., Flegal K., Furie K., et al., for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
2. Chobanian A.V., Bakris G.L., Black H.R., et al., for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report [published correction appears in JAMA. 2003;290:197]. JAMA 289 (2003) 2560-2572
3. Mancia G., De Backer G., Dominiczak A., et al., for the Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187
4. Williams B., Poulter N.R., Brown M.J., et al., for the BHS Guidelines Working Party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): Summary [published correction appears in BMJ. 2004;328:926]. BMJ 328 (2004) 634-640
5. Physicians' Desk Reference. 63rd ed (2009), Thomson Reuters, Montvale, NJ
6. Brenner B.M., Cooper M.E., de Zeeuw D., et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
7. Lewis E.J., Hunsicker L.G., Clarke W.R., et al., for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
8. Parving H.H., Lehnert H., Bröchner-Mortensen J., et al., for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
9. Mann J.F., Schmieder R.E., McQueen M., et al., for the ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008) 547-553
10. Mogensen C.E., Neldam S., Tikkanen I., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 321 (2000) 1440-1444
11. Viberti G., Wheeldon N.M., and for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106 (2002) 672-678
12. Barnett A.H., Bain S.C., Bouter P., et al., for the Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [published correction appears in N Engl J Med. 2005;352:1731]. N Engl J Med 351 (2004) 1952-1961
13. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (2000) 1582-1587
14. Cohn J.N., Tognoni G., and for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
15. Pfeffer M.A., Swedberg K., Granger C.B., et al., for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 362 (2003) 759-766
16. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [published corrections appear in N Engl J Med. 2000;342:1376 and N Engl J Med. 2000;342:748]. N Engl J Med 342 (2000) 145-153
17. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al., for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [published correction appears in N Engl J Med. 2004;350:203]. N Engl J Med 349 (2003) 1893-1906
18. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
19. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359 (2002) 995-1003
20. Schrader J., Lüders S., Kulschewski A., et al., for the MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 36 (2005) 1218-1226
21. Yusuf S., Diener H.C., Sacco R.L., et al., for the PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359 (2008) 1225-1237
22. Reboldi G., Angeli F., Cavallini C., et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: A meta-analysis. J Hypertens 26 (2008) 1282-1289
23. Krumholz H.M., Anderson J.L., Brooks N.H., et al., for the American College of Cardiology, American Heart Association Task Force on Performance Measures, Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction) [published correction appears in J Am Coll Cardiol. 2006;47:2140]. J Am Coll Cardiol 47 (2006) 236-265
24. Yusuf S., Teo K., Anderson C., et al., for the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial [published correction appears in Lancet. 2008;372:1384]. Lancet 372 (2008) 1174-1183
25. Ferdinand K.C. Recommendations for the management of special populations: Racial and ethnic populations. Am J Hypertens 16 (2003) 50S-54S
26. Chan J.C., Wat N.M., So W.Y., et al., for the Asian RENAAL Study Investigators. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. Diabetes Care 27 (2004) 874-879
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196]. JAMA 288 (2002) 2981-2997
28. Julius S., Alderman M.H., Beevers G., et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The LIFE study. J Am Coll Cardiol 43 (2004) 1047-1055
29. Weir M.R., Smith D.H., Neutel J.M., and Bedigian M.P. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: Relation to salt intake. Am J Hypertens 14 (2001) 665-671
30. Weir M.R., Ferdinand K.C., Flack J.M., et al. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension 46 (2005) 508-513
31. Law M., Wald N., and Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: A new preventive strategy. Health Technol Assess 7 (2003) 1-94
32. Conlin P.R., Gerth W.C., Fox J., et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 23 (2001) 1999-2010
33. Julius S., Nesbitt S.D., Egan B.M., et al., for the Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006) 1685-1697
34. Lindholm L.H., Persson M., Alaupovic P., et al. Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 21 (2003) 1563-1574
35. DREAM Trial Investigators, Bosch J., Yusuf S., Gerstein H.C., et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562